| Literature DB >> 29259829 |
Van Thi Ai Nguyen1,2, Truong Dang Le1, Hoa Ngoc Phan2, Lam Bich Tran2.
Abstract
Free fatty acids (FFAs) were obtained from hydrolyzed virgin coconut oil (VCO) by Candida rugosa lipase (CRL). Four factors' influence on hydrolysis degree (HD) was examined. The best hydrolysis conditions in order to get the highest HD value were determined at VCO to buffer ratio 1 : 5 (w/w), CRL concentration 1.5% (w/w oil), pH 7, and temperature 40°C. After 16 hours' reaction, the HD value achieved 79.64%. FFAs and residual hydrolyzed virgin coconut oil (HVCO) were isolated from the hydrolysis products. They were tested for their antibacterial activity against Gram-negative and Gram-positive bacteria, which can be found in contaminated food and cause food poisoning. FFAs showed their inhibition against Bacillus subtilis (ATCC 11774), Escherichia coli (ATCC 25922), Salmonella enteritidis (ATCC 13076), and Staphylococcus aureus (ATCC 25923) at minimum inhibitory concentration (MIC) of 50%, 60%, 20%, and 40%, respectively. However, VCO and HVCO did not show their antibacterial activity against these tested bacteria.Entities:
Year: 2017 PMID: 29259829 PMCID: PMC5702975 DOI: 10.1155/2017/7170162
Source DB: PubMed Journal: J Lipids ISSN: 2090-3049
Figure 1The rate of VCO to buffer (a), CRL concentration (b), pH (c), and temperature (d) effect on hydrolysis degree of VCO by CRL.
Figure 2Time course of VCO hydrolysis catalyzed by CRL.
Diameter of inhibition zone on 4 types of bacteria.
| Bacteria | Diameter of inhibition zone ± SD (mm) | ||
|---|---|---|---|
| FFAs | HVCO | VCO | |
|
| 11.33 ± 1.15 | 6 | 6 |
|
| 8.67 ± 0.58 | 6 | 6 |
|
| 10.33 ± 0.58 | 6 | 6 |
|
| 8.33 ± 0.58 | 6 | 6 |
Figure 3Antibacterial activity of VCO, HVCO, FFAs, and gentamicin against 4 types of tested bacteria.
Minimum inhibitory concentration of FFAs against four types of bacteria.
| Bacteria | MIC (%) |
|---|---|
|
| 50 |
|
| 60 |
|
| 20 |
|
| 40 |
Figure 4MIC of FFAs against Bacillus subtilis (a) and Escherichia coli (b).
Figure 5MIC of FFAs against Salmonella enteritidis (a) and Staphylococcus aureus (b).